The article explores how AI-powered translational safety intelligence helps pharmaceutical teams identify drug safety concerns sooner by integrating fragmented evidence across multiple sources. With novel drug modalities increasing data volume and complexity, the approach aims to enable confident safety decisions earlier in development when the consequences of a late-identified liability are highest.